Last reviewed · How we verify
NCT05769335: OMIT
Calories or Time Restriction to Alter Biomarkers of Aging and Diabetes
NA trial testing eCR in Obesity in 114 participants. Completed in 17 April 2025.
10 December 2024
Quick facts
| Lead sponsor | University of Adelaide |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 114 |
| Start date | 15 March 2023 |
| Primary completion | 10 December 2024 |
| Estimated completion | 17 April 2025 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- eCR
- dCR
- CR
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
University of Adelaide
Who can join
Adults 35 to 75, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Type 2 diabetes and cardiovascular disease are an increasing problem in Australia and around the world, and are partly linked to increased rates of obesity, together with sedentary lifestyles. This study will compare caloric restriction (CR) diets that restrict the amount of food that is eaten with CR diets that also restrict the time that the food is eaten, to either early or late in the day, on risk factors for type 2 diabetes and cardiovascular diseases over 2 months.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical Insights on Caloric Restriction Mimetics for Mitigating Brain Aging and Related Neurodegeneration.
Trisal A, Singh AK. · · 2024 · cited 9× · PMID 39412683 · DOI 10.1007/s10571-024-01493-2 -
Comparing the effectiveness of calorie restriction with and without time-restricted eating on the circadian regulation of metabolism – rationale and protocol of a three-arm randomised controlled trial in adults at risk of type 2 diabetes
Chang YJ, Turner L, Teong XT, Zhao L, et al · · 2024 · DOI 10.21203/rs.3.rs-5674165/v1
Verify or expand the search:
- PubMed search for NCT05769335
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other University of Adelaide trials
Trials by the same sponsor.
- NCT07013656 — Effects of Combined Administration of Calcium and L-tryptophan on Gut Functions and Blood Glucose in Healthy Humans · NA · not yet recruiting
- NCT06890507 — The Anti-Anginal Effects of N-Acetylcysteine (NAC) in Patients with Angina and Non-Obstructive Coronary Arteries (ANOCA) · Phase 2 · not yet recruiting
- NCT06942195 — Effects of Calcium on Gut Functions and Blood Glucose in Humans With Type 2 Diabetes · NA · recruiting
- NCT05682339 — Effects of Intragastric Quinine, Alone or Combined With L-isoleucine, on Postprandial Glycaemic Control · NA · completed
- NCT05720390 — Effects of Intragastric Quinine, Alone or Combined With L-leucine, on Postprandial Glycaemic Control · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05769335 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Adelaide
- Last refreshed: 9 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05769335.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing